Inventor · disambiguated record
Linda H. Malkas
Also filed as: MALKAS LINDA H
17 granted patents·13 pending applications·37 citations·filing 1998–2024
91Inventor score
Top patents by PatentIndex Score
30 records- 0192US11345656B2PCNA inhibitorsHOPE CITY·Filed 2020·Granted May 31, 2022·2 cites·24 claims
- 0290US12054447B2PCNA inhibitorsHOPE CITY·Filed 2022·Granted Aug 6, 2024·1 cites·20 claims
- 0390US10913706B2PCNA inhibitorsHOPE CITY·Filed 2019·Granted Feb 9, 2021·3 cites·42 claims
- 0489US10550070B2PCNA inhibitorsHOPE CITY·Filed 2016·Granted Feb 4, 2020·4 cites·22 claims
- 0588US9006396B2CsPCNA isoform antibodies and uses thereofHICKEY ROBERT J·Filed 2012·Granted Apr 14, 2015·8 cites·41 claims
- 0686US12435030B2PCNA inhibitorsHOPE CITY·Filed 2024·Granted Oct 7, 2025·0 cites·20 claims
- 0778US8278278B2Cell proliferation reducing cancer specific PCNA peptidesMALKAS LINDA H·Filed 2010·Granted Oct 2, 2012·5 cites·16 claims
- 0877US8653039B2Peptide based inhibition of caPCNA interaction in cancerHICKEY ROBERT J·Filed 2007·Granted Feb 18, 2014·2 cites·14 claims
- 0976US9527895B2CAPCNA peptide therapeutics for cancerHICKEY ROBERT J·Filed 2013·Granted Dec 27, 2016·2 cites·15 claims
- 1060US9187526B2Peptide based inhibition of caPCNA interaction in cancerHICKEY ROBERT J·Filed 2014·Granted Nov 17, 2015·0 cites·2 claims
- 1160US2025171404A1Pcna inhibitors and uses thereofHOPE CITY·Filed 2023·Application pending·0 cites
- 1258US2024245634A1Pcna inhibitors and egfr inhibitors for cancer treatmentHOPE CITY·Filed 2022·Application pending·0 cites
- 1358US2008206140A1Cspcna Isoform Antibodies and Uses ThereofUNIV INDIANA RES & TECH CORP·Filed 2006·Application pending·0 cites
- 1456US7723487B2Method for purifying cancer-specific proliferating cell nuclear antigenCS KEYS INC·Filed 2007·Granted May 25, 2010·1 cites·1 claims
- 1556US2019388504A1Capcna peptide therapeutics for cancerRLL LLC·Filed 2019·Application pending·0 cites
- 1655US10188699B2CAPCNA peptide therapeutics for cancerRLL LLC·Filed 2016·Granted Jan 29, 2019·0 cites·17 claims
- 1753US2016304559A1PEPTIDE BASED INHIBITION OF caPCNA INTERACTION IN CANCERHICKEY ROBERT J·Filed 2015·Application pending·0 cites
- 1852US2018362626A1csPCNA Isoform Antibodies And Uses ThereofRLL LLC·Filed 2018·Application pending·0 cites
- 1951US7932023B2csPCNA isoform modifications and uses thereofUNIV INDIANA RES & TECH CORP·Filed 2006·Granted Apr 26, 2011·0 cites·9 claims
- 2050US2015259407A1csPCNA Isoform Antibodies And Uses ThereofMALKAS LINDA H·Filed 2015·Application pending·0 cites
- 2148US2011195510A1csPCNA Isoform Modifications And Uses ThereofUNIV INDIANA RES & TECH CORP·Filed 2011·Application pending·0 cites
- 2247US2022048980A1csPCNA Isoform Antibodies And Uses ThereofRLL LLC·Filed 2021·Application pending·0 cites
- 2346US10420840B2Anticancer therapeutic agentsRLL LLC·Filed 2015·Granted Sep 24, 2019·0 cites·5 claims
- 2446US2013345231A1Anticancer therapeutic agentsHICKEY ROBERT J·Filed 2012·Application pending·0 cites
- 2542US2010240874A1Method for purifying cancer-specific proliferating cell nuclear antigenMALKAS LINDA H·Filed 2010·Application pending·0 cites
- 2637US7294471B2Method for purifying cancer-specific proliferating cell nuclear antigenCSKEYS LLC·Filed 2002·Granted Nov 13, 2007·0 cites·15 claims
- 2736US2012258482A1Pcna methyltransferaseHOELZ DEREK J·Filed 2010·Application pending·0 cites
- 2835US2006073477A1Altered DNA synthesome components as biomarkers for malignancyMALKAS LINDA H·Filed 2002·Application pending·0 cites
- 2932US6093543AMethod for detecting the presence of malignant cells using a multi-protein DNA replication complexUNIV MARYLAND·Filed 1998·Granted Jul 25, 2000·6 cites·23 claims
- 3032US6063575AAssay for measuring the activity and fidelity of DNA replication and kit thereforUNIV MARYLAND·Filed 1998·Granted May 16, 2000·3 cites·11 claims
Join the waitlist — get patent alerts
Get an alert when Linda H. Malkas files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →